Eli Moore

Eli Moore

Auto-generated profile, based on publicly available information

Eli Moore

ARC Centre of Excellence in Convergent Bio-Nano Science and Technology, Mawson Institute, University of South Australia , GPO Box 2471, Adelaide, South Australia 5001, Australia

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 November 2012 in Advanced Healthcare Materials
Verified
Journal Article
Closed access
PDF file
ESEmilie Secret
Emilie Secret
KSKevin Smith
Kevin Smith
VDValentina Dubljevic
Valentina Dubljevic
EMEli Moore
Eli Moore
PMPeter Macardle
Peter Macardle
NVNicolas Voelcker
Nicolas Voelcker

19 August 2014 in ACS Applied Materials & Interfaces
Verified
Journal Article
Closed access
EMEli Moore
Eli Moore
BDBahman Delalat
Bahman Delalat
RVRoshan Vasani
Roshan Vasani
GMGordon McPhee
Gordon McPhee
HTHelmut Thissen
Helmut Thissen
NVNicolas Voelcker
Nicolas Voelcker

1 June 2014 in Nanomedicine
Verified
Journal Article
Closed access
MBManpreet Bariana
Manpreet Bariana
MAMoom Sinn Aw
Moom Sinn Aw
EMEli Moore
Eli Moore
NVNicolas Voelcker
Nicolas Voelcker
Dusan LosicDusan Losic
Dusan Losic
This study aimed to demonstrate radiofrequency (RF)-triggered release of drugs and drug carriers from drug-eluting implants using gold nanoparticles as energy transducers. Titanium wire with a titania nanotube layer was used as an implant loaded with indomethacin and micelles (tocopheryl PEG succinate) as a drug and drug carrier model. RF signals were generated from a customized RF generator to trigger in vitro release. Within 2.5 h, 18 mg (92%) of loaded drug and 14 mg (68%) of loaded drug carriers were released using short RF exposure (5 min), compared with 5 mg (31%) of drug and 2 mg (11%) of drug carriers without a RF trigger. Gold nanoparticles can effectively function as RF energy transducers inside titania nanotubes for rapid release of therapeutics at arbitrary times. The results of this study show that RF is a promising strategy for triggered release from implantable drug delivery systems where on-demand delivery of therapeutics is required.

9 March 2022 in OncoImmunology
Verified
Journal Article
Open access
LTLih Y. Tan
Lih Y. Tan
MCMichaelia P. Cockshell
Michaelia P. Cockshell
EMEli Moore
Eli Moore
KMKay Khine Myo Min
Kay Khine Myo Min
MOMichael Ortiz
Michael Ortiz
Claudine BonderClaudine Bonder
Claudine Bonder
The progression of cancer is facilitated by infiltrating leukocytes which can either actively kill cancer cells or promote their survival. Our current understanding of leukocyte recruitment into tumors is largely limited to the adhesion molecules and chemokines expressed by conventional blood vessels that are lined by endothelial cells (ECs). However, cancer cells themselves can form their own vascular structures (a process known as vasculogenic mimicry (VM)); but whether they actively participate in the recruitment of leukocytes remains to be elucidated. Herein, we demonstrate that VM-competent human melanoma cell lines express multiple adhesion molecules (e.g. CD44, intercellular adhesion molecule (ICAM)-1 and junction adhesion molecules (JAMs)) and chemokines (e.g. CXCL8 and CXCL12) relevant for leukocyte recruitment. Microfluidic-based adhesion assays revealed that similar to ECs, VM-competent melanoma cells facilitate the rolling and adhesion of leukocytes, particularly monocytes, under conditions of shear flow. Moreover, we identified ICAM-1 to be a key participant in this process. Transwell assays showed that, similar to ECs, VM-competent melanoma cells facilitate monocyte transmigration toward a chemotactic gradient. Gene expression profiling of human melanoma patient samples confirmed the expression of numerous leukocyte capture adhesion molecules and chemokines. Finally, immunostaining of patient tissue microarrays revealed that tumors with high VM content also contained higher numbers of leukocytes (including macrophages). Taken together, this study suggests an underappreciated role of VM vessels in solid tumors via their active participation in leukocyte recruitment and begins to identify key adhesion molecules and chemokines that underpin this process.

1 July 2014 in Biomacromolecules
Verified
Journal Article
Closed access
EMEli Moore
Eli Moore
BDBahman Delalat
Bahman Delalat
RVRoshan Vasani
Roshan Vasani
HTHelmut Thissen
Helmut Thissen
NVNicolas Voelcker
Nicolas Voelcker

31 August 2013 in Progress in Surface Science
Verified
Journal Article
Closed access
EMEli Moore
Eli Moore
HTHelmut Thissen
Helmut Thissen
NVNicolas Voelcker
Nicolas Voelcker